4.7 Review

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis

期刊

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 114, 期 -, 页码 252-260

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.11.009

关键词

COVID-19; SARS-CoV-2; Vaccine; Effectiveness; Real-world

向作者/读者索取更多资源

A meta-analysis showed that COVID-19 vaccines have high efficacy in real-world settings, providing significant protection against SARS-CoV-2-related diseases. Fully vaccinated individuals had vaccine effectiveness of 89.1% against infection, 97.2% against hospitalization, 97.4% against ICU admission, and 99.0% against death.
Objective: To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Methods: Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. Results: A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6-92.6%), 97.2% (95% CI 96.1-98.3%), 97.4% (95% CI 96.0-98.8%), and 99.0% (95% CI 98.5-99.6%), respectively. The VE against infection in the general population aged >16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8-94.4%), 83.8% (95% CI 77.1-90.6%), and 95.3% (95% CI 92.0-98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%. Conclusions: The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real world settings.(c) 2021 Zhengzhou University. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据